PEPTIDE CORTEXThe library
← The library

LL-37

researchImmune/Anti-inf
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeAntimicrobial / Immune
MechanismHuman cathelicidin antimicrobial peptide (experimental)
EffectsInnate immune antimicrobial signaling (experimental)
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published2 sourced
Clinical trialVenous leg ulcers (Grönberg, Wound Repair Regen 2014)
RouteTopical, applied to the ulcer
FrequencyTwice weekly, 4 weeks
StartingArms: 0.5, 1.6 or 3.2 mg/mL
EscalationNone
TargetBest effect at 0.5 and 1.6 mg/mL; 3.2 mg/mL was less effective with more local reactions

Topical wound-application doses; not transferable to injection.

Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous
FrequencyOnce daily, often 5 days/week
Starting100-200 mcg/day SC
EscalationUp to 500 mcg/day
Target100-500 mcg/day
Cycle2-4 weeks, then a break (length not stated)

"No published human trial has tested subcutaneous LL-37."

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not FDA-approved; potential inflammation; avoid self-administration

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.